Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

A University of Pennsylvania biotechnology company that aims to treat autoimmune diseases by reengineering cells within the ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Summary: New research reveals how a tiny chemical mark on RNA helps wire the brain during development. Scientists discovered that m6A methylation regulates the production of proteins essential for ...

Stanley Black & Decker has designated Christopher Nelson to succeed Donald Allan Jr. as president and chief executive of the tool maker, effective Oct. 1. Financial services companies like BNY and ...

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of ...

The mRNA metabolism passively shapes the levels of an mRNA modification called m6A within a steady-state cell and upon stress.

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna's messenger RNA flu vaccine candidate has shown has shown positive results in a late-stage trial. The biotechnology company said Monday its seasonal influenza vaccine candidate, mRNA-1010, ...

The FDA has approved its requested updated versions of expanded warning labels for COVID-19 vaccines. As Healio previously ...